| Literature DB >> 29283407 |
An-Jun Liu1, Juan Yu2, Hai-Yu Ji3, Hong-Cui Zhang4, Yan Zhang5, Hui-Ping Liu6.
Abstract
The polysaccharides of Astragalus membranaceus have received extensive study and attention, but there have been few reports on the extraction of these polysaccharides using cold water (4 °C). In this study, we fractionated a novel cold-water-soluble polysaccharide (cAMPs-1A) from Astragalus membranaceus with a 92.00% carbohydrate content using a DEAE-cellulose 52 anion exchange column and a Sephadex G-100 column. Our UV, Fourier-transform infrared spectroscopy (FTIR), high-performance gel permeation chromatography, and ion chromatography analysis results indicated the monosaccharide composition of cAMPs-1A with 1.23 × 10⁴ Da molecular weight to be fucose, arabinose, galactose, glucose, and xylose, with molar ratios of 0.01:0.06:0.20:1.00:0.06, respectively. The UV spectroscopy detected no protein and nucleic acid in cAMPs-1A. We used FTIR analysis to characterize the α-d-pyranoid configuration in cAMPs-1A. In addition, we performed animal experiments in vivo to evaluate the antitumor and immunomodulatory effects of cAMPs-1A. The results suggested that cAMPs-1A oral administration could significantly inhibit tumor growth with the inhibitory rate of 20.53%, 36.50% and 44.49%, respectively, at the dosage of 75,150, and 300 mg/kg. Moreover, cAMPs-1A treatment could also effectively protect the immune organs, promote macrophage pinocytosis, and improve the percentages of lymphocyte subsets in the peripheral blood of tumor-bearing mice. These findings demonstrate that the polysaccharide cAMPs-1A has an underlying application as natural antitumor agents.Entities:
Keywords: Astragalus membranaceus; antitumor; cold-water-soluble polysaccharide; immunomodulation; structure characterization
Mesh:
Substances:
Year: 2017 PMID: 29283407 PMCID: PMC6017583 DOI: 10.3390/molecules23010062
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The standard curve (a) and results of HPGPC of cAMPs-1A (b).
Figure 2Results of IR spectrum on cAMPs-1A.
Figure 3Ion chromatograms of standard monosaccharide (a) and cAMPs-1A (b). Peak identity: 1—fucose, 2—rhamnose, 3—arabinose, 4—galactose, 5—glucose, 6—xylose, 7—mannose, 8—glucuronic acid, 9—galacturonic acid.
Inhibitory effect of cAMPs-1A on the immune organs indexes and growth of H22 tumor.
| Treatment | Dose (mg/kg) | Thymus Index (mg/g) | Spleen Index (mg/g) | Tumor Weight (g) | Inhibitory Rate (%) |
|---|---|---|---|---|---|
| Blank group | - | 3.30 ± 0.66 | 4.52 ± 0.47 | - | - |
| Model group | - | 1.51 ± 0.17 b | 7.93 ± 0.46 b | 2.63 ± 0.24 | - |
| 5-Fu | 30 | 1.21 ± 0.11 a | 3.87 ± 0.15 a | 1.41 ± 0.13 a | 46.39 |
| cAMPs-1A group | 75 | 1.89 ± 0.16 a | 6.45 ± 0.32 a | 2.09 ± 0.16 a | 20.53 |
| cAMPs-1A group | 150 | 2.47 ± 0.21 a | 5.89 ± 0.40 a | 1.67 ± 0.14 a | 36.50 |
| cAMPs-1A group | 300 | 3.08 ± 0.36 a | 4.62 ± 0.29 a | 1.46 ± 0.11 a | 44.49 |
Note: a p < 0.05 compared to model group; b p < 0.05 compared to blank group.
Figure 4Effects of cAMPs-1A on macrophages pinocytosis (a) and NK cells activity (b) in H22-bearing mice. Note: a p < 0.05 compared to model group; b p < 0.05 compared to blank group.
Effects of cAMPs-1A on the distribution of T cells subsets in peripheral blood.
| Groups | Dose (mg/kg) | CD4+ (%) | CD8+ (%) |
|---|---|---|---|
| Blank group | - | 37.66 ± 2.68 | 18.25 ± 1.40 |
| Model group | - | 29.22 ± 2.61 b | 15.26 ± 1.38 b |
| 5-Fu | 30 | 28.43 ± 2.24 | 14.84 ± 1.41 |
| cAMPs-1A groups | 75 | 31.43 ± 3.11 | 16.26 ± 1.12 |
| 150 | 33.79 ± 2.70 a | 17.83 ± 0.93 a | |
| 300 | 37.24 ± 3.74 a | 19.63 ± 3.42 a |
Note: a p < 0.05 compared to model group; b p < 0.05 compared to blank group.
Figure 5Effects of cAMPs-1A on T cells subsets distribution in peripheral blood of H22-bearing mice.